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LRRK2 is a multi-domain protein expressed widely in organs. The mutations of LRRK2 
are related to Parkinson’s disease. The Roc domain in LRRK2 is a Ras GTPase, and its 
GTP hydrolysis activity has been proved to regulate kinase activity of the kinase domain. 
With the structure of GDP bound Roc domain (inactive state) solved, we intend to 
determine the structure of GTP analog bound Roc domain (active state). The change 
between them should reveal the dynamic conformational changes in the ROC GTPase 
domain, and provide important clues on the mechanisms of GTP hydrolysis and 
signaling. We engineered Roc based on surface entropy reduction and used GDP, AlF4
- 
and GppNp as GTP analogs. Mutants of Roc crystallized but only GDP was found in the 
binding pocket. 
A6 is a vaccinia virus protein is expressed during late translation and is packed in the 
viron core. The absence of A6 dislocates some viron proteins, disrupts the recruitment of 
virus membrane and stops virus maturation. There is no homologue structure of A6, so 
we intend to solve the structure and compare it with other known functional domain 
structures. In this way, we can expand our understanding of the role A6 plays during 
vaccinia virus replication. A6 and its homologues are recalcitrant to crystallization, but 
surface entropy reduction and truncation based on limited proteolysis promoted 
crystallization. The mutant AC crystal diffracted to 4 Å and truncated mutant C diffracted 
to 8 Å. Antibodies including Fabs and SdAbs were also used to assist crystallization.  But 
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Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting six 
million people around the world. Patients of PD suffer from motor abnormality caused by loss of 
dopamine. Leucine-rich Repeat Kinase 2 (LRRK2) is a multi-domain protein expressed broadly 
in organs including brain, heart and liver. The mutations of LRRK2 are mainly found in patients 
of PD, and a major part of pathological mutations are located in the central part of LRRK2, 
including a Ras of Complex (ROC) GTPase domain, a kinase domain and a domain in between 
called C-terminal of Roc (COR) domain. Previous research has found that the Roc domain 
regulates kinase activity as a binary switch through a GTP/GDP bound cycle. The structure of the 
GDP-binding Roc (inactivated state) has been solved previously and we intend to determine the 
structure of ROC in its activated state. The expected results would reveal the dynamic 
conformational changes in the ROC GTPase domain, providing important clues on the 
mechanisms of GTP hydrolysis and signaling. We engineered Roc based on surface entropy 
reduction and used GDP, AlF4- and GppNp as GTP analogs. Mutants of Roc crystallized but only 





Vaccinia viruses undergo a series of morphological changes during replication. A6 is a vaccinia 
virus protein essential for vaccinia virus assembly and it was proposed to be involved in vaccinia 
virus morphogenesis by recruiting membrane from the infected cell, as well as other important 
proteins to virion factories. Although the sequence of A6 is highly conserved throughout 
vertebrate poxvirus family, there are no known homologs outside the poxvirus family to suggest 
its function, or any homolog structure inside the family. We intended to solve the structure of A6 
by x-ray crystallography to obtain insights into its function. By comparing the structure of A6 
with other known functional domain structures, we can expand our understanding of the role A6 
plays during vaccinia virus replication. A6 and its homologues are recalcitrant to crystallization, 
but surface entropy reduction and truncation based on limited proteolysis promoted 
crystallization. The mutant AC crystal diffracted to 4 Å and truncated mutant C diffracted to 8 Å. 
Antibodies including Fabs and SdAbs were also used to assist crystallization.  But more 










Protein x-ray crystallography is widely used to determine the 3-D structures of proteins or protein 
complexes. It involves several steps including protein expression, purification, crystallization, 
data collection and processing, and structure determination refinement and validation. In this 
chapter, I will discuss protein x-ray crystallography by reviewing each step on the basis of my 
experiments and understanding. 
 
B. Protein Expression and Purification 
The first step of protein x-ray crystallography is to prepare milligram scale of a protein with 
≥95% purity.  The protein can be either purified from a natural source or overexpressed by an 
expression system such as bacteria, yeast, insect or mammalian cells.  
In bacterial expression systems, it is easy and fast to make the constructs and express proteins. 
But the lack of the eukaryotic post-translational modifications may result in insoluble or unfolded 




Yeasts grow comparably fast as bacteria and are also easy to culture. Yeast expression systems 
contains the eukaryotic post-translation modification. But the chitinaceous cell wall of yeasts is 
recalcitrant to lysis, so they are less commonly used to produce cytoplasmic proteins. A signal 
peptide sequence needs to be carefully selected for the expression of secreted proteins by yeasts. 
In contrast, insect and mammalian cell expression systems are both time consuming and 
expensive for construction and protein expression, but they can express eukaryotic proteins with 
correct post-translational modification or folding.  
For experiments carried out in this thesis, I mainly used Escherichia coli (E. coli) system for 
overexpression of the targeted proteins.   
1. Protein Overexpression from E. coli 
Throughout our crystallographic studies, E. coli BL21 Gold DE3 strains (Strategene) was used 
for all protein expression. (Thony, Neuheiser et al. 1998, Johnson, Bornemeier et al. 1999, 
Wagner, Betzenhauser et al. 2006, Betzenhauser, Wagner et al. 2008) A set of expression vectors 
were made in house based on the backbone of the pET vectors (Qiagen) (Gao, Cao et al. 2009) 
with the T7 promoter was also utilized. Gene encoding target protein was amplified by 
polymerase chain reaction (PCR) and then ligated to specific expression vector for 
overexpression as 6xHis tagged fusions. N-terminal TEV cleavable 6xHis tag fusion, C-terminal 
permanent 6xHis tag fusion, SUMO fusion and MBP fusion were used in my projects and will be 
described in following chapters. The plasmids were subsequently transformed into E. coli BL21 
Gold DE3 strain by electroporation.  
BL21 Gold DE3 cell has lambda DE3 lysogen carrying the T7 RNA polymerase under the control 
of lacUV5 promoter. Also, deletion of lon protease and mutation on OmpT protease in BL21 
Gold DE3 cell prevent expressed target protein from degradation by these proteases. This 




constructs, as the transformation efficiency is increased to >1x108 cfu/ug of pUC 18 DNA, by 
selecting the Hte phenotype. Moreover, enA gene encoding endonuclease I is disabled to avoid 
plasmid DNA degradation. Therefore, using this strain shortens the experimental time by up to 
50%. (Stratagene competent cells manual) 
The mechanism of pET expression vectors are as follows: (1) the lacI gene encodes the lac 
repressor; (2) the lac repressor binds to the lacUV5 promoter and represses binding of T7 RNA 
polymerase to T7 promotor; (3) the presence of isopropyl β-D-1-thiogalactopyranoside (IPTG) 
induces the lac repressor to dissociate from the lacUV5 promoter and allows the bindin of T7 
RNA polymerase. Thus, the target gene ligated to pET expression vector would be transcribed for 
protein expression. (Gao, Cao et al. 2009)  
 
Figure 2-1: Schematic illustration of pET vector. 
2. Protein Purification 
To facilitate protein purification from E. coli, the target proteins are usually fused with tags, such 
as polyhistidine (6His) (Hengen 1995), Glutathione S-transferase (GST) (Benard and Bokoch 
2002) and maltose binding protein (MBP) (Nallamsetty and Waugh 2007).  Each tag binds to a 
specific resin allowing affinity purification.  
A common protocol for purification of 6xHis fusion protein is described here. Frozen cell pellets 
were typically resuspended with buffer A (20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 20 mM 




Sonic dismembrator from Fisher Scientific), or high-pressure homogenizer (EmulsiFlex-C5). 
Protease inhibitors were used to prevent protein degradation and DNase was added to digest the 
bacterial genome DNA in order to reduce viscosity. The cell lysate was fractionated into insoluble 
and soluble components by high-speed centrifugation (Thermo scientific Sorvall RC 6+ centrifuge) 
at 15,000g for 0.5 hour at 4°C. The supernatant is subsequently mixed with proper amount of 
Nickel-Nitrilotriacetic Acid (Ni-NTA) resin (GE Healthcare), typically 1 ml resin for 10 mg of 
6xHis tagged protein. The mixture is incubated on a platform rocker at 4°C for 1 hour to allow 
efficient binding before transferred into a small gravity flow column. The unbound material is 
separated from Ni-NTA resin as flow through. 20 column volumes of Buffer A is used to wash off 
the nonspecifically bound contaminants, and the target protein is eluted with buffer B (20 mM Tris-
HCl, pH8.0, 500 mM NaCl, 250 mM Imidazole, 10% glycerol). For crystallization purposes, the 
artificial 6xHis tag and the flexible linker need to be removed by specific proteases. Ubiquitin-like 
protein-processing protease Ulp1 is used to recognize SUMO and cleaves at its C- terminus after 
GG (Hanington, Barreda et al. 2006) and tobacco etch virus (TEV) protease is used to cleave 
between Q and S/G of the consensus sequence E-Xaa-Xaa-Y-Xaa-Q-S/G (Carrington and Dougherty 
1988). After digestion, the mixture of tag-cleaved protein, the tagged protease and uncleaved 
protein is applied to Ni-NTA resin again. Only tag-cleaved protein passes through. For further 
purification, size exclusion chromatography (HiLoad 16/60 Superdex 200 column or Superdex 200 
10/300 GL column from GE Healthcare) (Paul-Dauphin, Karaca et al. 2007) and ion-exchange 
chromatography (column Q and S) (Sakash and Kantrowitz 2000) are used. Size exclusion 
chromatography separates proteins depending on their molecular weight and ion-exchange 





Figure 2-2: The scheme of two-step Nickel purification. 
 
C. Protein Crystallization  
1. Mechanism 
Protein crystals are formed by protein molecules packing together through weak intermolecular 
interactions, including dipole-dipole interactions, hydrogen bonds, salt bridges, and van der 
Waals (vdW) interactions. To achieve this process, a saturated protein concentration should be 
reached. Figure 2-3 shows the protein solubility phase diagram at a given temperature.  It 
explains that protein reaches its saturated state by increasing either protein concentration or the 





Figure 2-3: Protein solubility phase diagram. Adapted from (Rupp 2010).  
Besides the availability of sufficient protein molecules, spontaneous crystal formation also 
requires a negative free energy. Free energy of crystallization ∆G is calculated from equation 
(2.1) 
 ∆G= ∆H-T(∆Sprotein+∆Ssolvent) (2.1) 
Given the weak interaction forming the protein crystal package, ∆H is only weakly negative 
during the protein crystallization. ∆Sprotein is the entropy that the protein gains from the translation 
and rotation of protein molecules during crystallization and ∆Ssolvent is the entropy that the solvent 
obtains from the release of water molecules from the protein surface. As the temperature during 




releasing ordered water molecules from hydrophobic residues has to be larger than the entropy 
lost from the forming of regular network of interactions (Derewenda and Vekilov 2006). 
2. Protein Crystallization Methods 
In order to obtain a crystal, protein solution is mixed with hundreds of crystallization solutions. A 
crystallization solution contains a buffer to keep a specific pH, a certain concentration 
precipitants and additives. With this crystallization solution, several techniques are used to drive a 
protein solution into a saturation state. Figure II-4 presents five widely used techniques in protein 
crystallization (Rupp 2010):  
(1) Hanging-drop vapor diffusion;  
(2) Sitting-drop vapor diffusion;  
(3) Micro-dialysis;  
(4) Micro-batch under oil;  
(5) Free-interface diffusion.   
In hanging-drop vapor diffusion, a mixture of protein solution and crystallization solution with a 
certain ratio is placed on a cover slide, which hangs above the crystallization solution in a sealed 
well.  
In the sitting-drop vapor diffusion, the mixed protein solution and crystallization solution is 
placed on a shelf or a post. Compared with the hanging-drop vapor diffusion, the sitting-drop 
vapor diffusion is compatible for a robotic dispenser.  
In micro-dialysis, protein is placed in a dialysis bag. The membrane of bag has specific size pores 




outside of dialysis bag. This method is not normally used in a large-scale initial screening, but 
would be suitable for growing large crystals under known conditions. 
In micro-batch crystallization, the protein solution is mixed with the crystallization solution, and 
is placed under oil allowing the solvent to slowly evaporate from the mixture.  
In the free-interface diffusion, protein solution and crystallization solution are placed in two 
chambers, and equilibrate against each other by channels. 
 
Figure 2-4: Five protein crystallization techniques. Adapted from (Rupp 2010). 
 
D. X-ray Diffraction of Protein Crystals 
A crystal is the periodic assembly of basic unit cells. So understanding the diffraction of crystal 
begins with understanding of the unit cell.  




The unit cell is the smallest unit in the protein crystal, and is defined by vectors a, b and c, and the 
angles α, β and γ (Figure 2-5). Depending on the values of these six parameters, protein crystals 
are divided into seven crystal systems, which are triclinic, monoclinic, orthorhombic, tetragonal, 
trigonal, hexagonal and cubic (Figure 2-5). 
                                      
 
Figure 2-5: Unit cell and seven crystal systems. Copied from 
http://chemwiki.ucdavis.edu/Under_Construction/Lardbucket/Chapter_12/12.2_The_Arrangemen
t_of_Atoms_in_Crystalline_Solids. 
Besides these seven shape systems, unit cells are further defined by the positions of molecules 





Figure 2-6: Primitive (P), body centred (I) and face centred (F) cells. Copied from 
http://www.doitpoms.ac.uk/tlplib/crystallography3/unit_cell.php 
Combined seven crystal systems with three lattice types, it produces 14 Bravais lattices for 





Figure 2-7: 14 Bravais lattices. Copied from 
http://www.seas.upenn.edu/~chem101/sschem/solidstatechem.html. 
2. X-ray Scattering by Crystals 
Successfully obtaining the crystal is the important step toward the eventual structure 
determination. The qualified single crystals will be used for data collection from x-ray diffraction. 
When a beam of x-ray penetrates the protein crystals, most of them pass through the crystals, 
while a small amount of them will be scattered by the atoms. The scattering occurs from two 
processes. 1) Coherent scattering, also called Thomson scattering, happens when the electron is 




same frequency, and gives out a second ray in the same wavelength and opposite phase. 2) 
Incoherent scattering, also known as Comton scattering, is random fluctuation of EM rays and is 
usually ignored in crystallography.  
X-ray diffraction can only occur in certain directions with respect to the incident beam, which is 
defined as the Bragg law (Figure 2-8). In Bragg law, the crystal lattices are taken as a series of 
parallel planes with interplanar spacing distance d. The x-rays of wavelength λ impinge on these 
planes at an angle θ. Only when θ meets the condition 2dsin θ=n λ (n is an integer), the rays 
diffracted from successive planes in crystals are in phase with each other, producing a strong 
diffracted beam.(Blundell and Johnson 1976) 
 
 
Figure 2-8: Bragg’s law.     
The scattering of x-ray by two adjacent particles is diagrammatized as in Figure 2-9, with S0 




 ∆𝜑 = 2𝜋(𝑠1 − 𝑠0)r = 2𝜋S ∙ 𝑟 (2.2) 
 
 
Figure 2-9: The scattering of x-ray by two atoms. Adopted from (Rupp 2010). 
They can generate the maximal constructive interference when ∆𝜑𝑚𝑎𝑥 = 2𝜋S ∙ 𝑟 = 𝑛 ∙ 2𝜋 and n 
being integer. When taking the three dimensions into consideration, we can obtain the Laue 
equation as (2.3):  
 S ∙ a = 𝑛1, S ∙ b = 𝑛2, and S ∙ c = 𝑛3 (2.3) 
 
The a, b, c are unit cell vectors and the integers are related to Miller indices (h, k, l). 
3. Reciprocal Lattice        
The crystal lattices are treated as a series of parallel planes and the periodic repeat of the Bravais 
lattice. In order to visualize the spacing of reflections that can be collected, crystallographers 
construct an imaginary lattice, the reciprocal lattice, to represent the spacial organization of the 
Fourier transformation of the Bravais lattice. The Miller indices (h, k, l) are the smallest 
denominators in three-dimension lattice planes, which are related reciprocally to a, b, and c of the 




One point in the real lattice is described as a position vector r and one point in the reciprocal 










) = I 
(2.4) 
When the points in both real and reciprocal lattices are defined by planes, the corresponding 










) = (𝐀∗) 𝐡T  
(2.5) 
with h being the index(column) vector and (A*)T being the matrix containing the reciprocal 
vectors in its column (Rupp 2010). 
If we bring in Bragg’s Law 2dsin θ=n λ (n is an integer) to determine when the diffraction 
happens, we shall find that for the set of lattice planes h, k, l, its reciprocal lattice plane vector 











That is to say, when a point in reciprocal lattice meets the circle with origin at the crystal and a 
radius being 1/λ (wavelength), which is defined as Ewald sphere, this point satisfies Bragg’s Law 
and a reflection can be observed if CCD detector is present.(Ayer 1989)    
 
E. The Mathematics of Crystallography 
In protein crystallography, each reflection is the x-ray diffracted from the crystal and thus can be 




 𝑓(𝑥) = 𝐹𝑠𝑖𝑛2𝜋(ℎ𝑥 + 𝛼) 𝑜𝑟 𝑓(𝑥) = 𝐹𝑐𝑜𝑠2𝜋(ℎ𝑥 + 𝛼) (2.7) 
In these functions, the constant F specifies the amplitude of the wave; the constant h specifies the 
frequency of the wave; the variable x implies the position of the wave from the origin; and the 
constant α is the phase of the wave. 
For the complicated wave, it can be described as the sum of a lot of simple waves, which is called 
a Fourier series, and written in the following form.  
 
𝑓(𝑥) = ∑ 𝐹ℎ
𝑛
ℎ=0
𝑐𝑜𝑠2𝜋(ℎ𝑥 + 𝛼ℎ  ) 𝑜𝑟 𝑓(𝑥) = ∑ 𝐹ℎ
𝑛
ℎ=0
𝑠𝑖𝑛2𝜋(ℎ𝑥 + 𝛼ℎ  ) 
(2.8) 
In these two equations, the waveforms of cosine and sine can be combined as 
[cos2απ(hx)+isin2π(hx)],  and the equation for the description of reflection is described as:  
 
𝑓(𝑥) = ∑ 𝐹ℎ
𝑛
ℎ=0
[𝑐𝑜𝑠2𝜋(ℎ𝑥) + 𝑖𝑠𝑖𝑛2𝜋(ℎ𝑥)] 
 
(2.9) 
Further, cosθ+isinθ=eiθ,  so the description of reflection is described as:  
 
𝑓(𝑥) = ∑ 𝐹ℎ
𝑛
ℎ=0





For the three-dimensional wave with the variable h, k, l, the f(x,y,z) is written in the form:  
 




















In this equation F(h) is called the Fourier transformation of f(x), the units of the variable h are 
reciprocals of the units of x.  For the three-dimensional wave, fourier transform of f(x,y,z), F(h, k, 
l) is described as follows:  
 





In this equation, F(h, k, l) is the structure factor that describes reflection hkl; f(x, y, z) is the 
electron density at position (x, y, z); and dxdydz is equal to the volume V. This equation also is 
written as: 
 





As the Fourier transformation operation is reversible, the electron density ρ(x, y, z) is the 
transformation of the structure factors, (Rupp 2010) 
 













F. Data Collection, Processing and Analysis 




Data collection in protein crystallography is the recording of the intensity of all reflections 
diffracted (or as much as possible) from protein crystals. Several factors affect the data quality, 
such as x-ray source, cryo-condition, exposure time and the quality of crystal.  
Protein crystallographers use both the in-house and synchrotron x-ray source. The in-house x-ray 
source produces x-ray through bombarding the metal target (most commonly copper) with 
accelerated electrons, which displace electrons from a low-lying orbital in target metal atom. .For 
Cu anode x-ray generator, electrons dropping from the L shell of Cu to replace displaced K shell 
electrons emit X rays of 1.54 Å wavelength.  
At the synchrotron x-ray source, electrons in the storage rings accelerate to velocities near the 
speed of light. These electrons emit synchrotron radiation in a wide range of wavelengths when 
forced into curved motion by powerful magnets. X-rays at selectable wavelengths are provided by 
focusing mirrors and monochromators system. In US, synchrotron x-ray sources are available at 
Advanced Photon Source at Argonne National Laboratory, Cornell High-energy Synchrotron 
Source, National Synchrotron Light Source at Brookhaven National Laboratory, and Advanced 
Light source at Lawrence Berkeley National Laboratory. 
The synchrotron x-ray source is much more powerful than the in-house source, and thus can be 
utilized to collect high resolution data sets, or derivative data sets for phasing calculation, which 
will be described later. 
Data collection is generally performed at 100 K to minimize the radiation damage and extend the 
survival time of crystals during data collection. However, this low temperature could also induce 
ice formation within the crystals that may disrupt protein lattices and cause either loss of 
diffraction or lead to anisotropic diffraction. To prevent this commonly found problem associated 
with cryogenic condition, an optimal cryoprotectant at the correct concentration is necessary.  




sucrose, or salt at various concentrations are widely chosen as cryo-solutions, whose 
concentrations have to be precisely determined empirically. 
Before starting the full data collection, several images are collected to optimize the exposure 
time, the distance between crystal and detector, and strategy for data collection.  
Longer exposure time will surely increase the diffraction intensity and enhance weak diffraction, 
but it will also boost up radiation damage to the crystal. The distance between crystal and detector 
should be far enough for the detector to collect all diffraction spots, especially those high 
resolution spots at the edge, but not too far so spots can be distinctly separated. Depending on the 
symmetry of the crystal (described in C.1), the angle the crystal needs to rotate so a full set of 
data can be collected differs. We certainly want as much data as possible, but the longer the 
crystal is exposed to x-rays, the bigger the radiation damage is. So pros and cons are carefully 
considered during strategy optimization. 
2. Data Processing 
After the data collection, raw data set is processed to assign the unique indices (h, k, l) with their 
observed intensities.  Data processing involves several steps, including indexing, integration, and 
scaling. Indexing is the process to determine the unit cell parameters, crystal orientation and 
decide the actual Bravais lattice symmetry of the given crystal. Integration is to identify the 
background and spot region and measure the intensity of the spot. Scaling is the process to correct 
the diffraction intensities. Various physical factors lead to observed intensities being on different 
scales. These factors include:  1) the incident beam and the camera; 2) the crystal and the 
diffracted beam; and 3) the detector. After the scaling, the multiple measurements of equivalent 
reflections are merged to produce unique reflection. 




The quality of the collected dataset is analyzed by several statistical parameters: the highest 
resolution, completeness, redundancy, the number of unique reflections, the mean signal to noise 
ratio of the reflections (I/σI) and Rmerge. The data quality indicator Rmerge is the linear merging R 
factor from given amount (N) of reflections h within a resolution range. 
 
𝑅𝑚𝑒𝑟𝑔𝑒 =









𝐼(𝐡)̅̅ ̅̅  is the averaged intensity of every reflection. Rmerge is computed for entire data set or for each 
resolution shells. When relative error increases and reflections are weak, the Rmerge increases 
rapidly in high resolution. 
A typical ‘good’ data set meets the following criteria. It has high resolution. The ideal 
completeness is 100%.  The redundancy is reasonable according to symmetry. Every unique 
reflections should be collected at least once. The lowest mean signal to noise ratio of the 
reflections (I/σI) presenting at the highest resolution shell has a cutoff value 2.0. Rmerge is low. 
 
G. Structure Determination 
1. Crystallographic Phase Problem 
When reconstructing electron density using the Fourier back-transformation, we can reverse the 
equation (2.15) we described in chapter D as below, 
 









|𝐹(𝐡) | is proportional to the square root of I, thus it is measurable, leaving the phase information 
𝜑(h) lost. (Taylor 2003) 
This is the well-known ‘Phase Problem’ in crystallography. Phase problem can be solved by ab 
initio determination via experimental procedures, such as from anomalous scattering, or by 
mathematic calculations from available phases obtained from an existing model, using molecular 
replacement. 
2. Molecular Replacement 
If a model from an already determined homolog structure is available, one can obtain the phases 
of an unknown protein rapidly from its diffraction intensities. 
If the unknown protein and the model are isomorphous, they not only share the same space group 
and unit cell dimensions, but also have almost the same atoms at the same position. In this case, 
the phases of crystal of unknown protein can be directly computed from its intensity. 
If they are not isomorphous, as in most cases, we can determine the model position and 
orientation by comparing the calculated structure factors amplitudes from the model and 
measured amplitudes from the unknown protein. Before digging into details, we need to first 
understand the concept of the Patterson Function. 
a. Patterson Function 
The Patterson function arises from the autocorrelation of molecular structure. The value is 
directly calculated from the diffraction intensity by putting each atom at the origin, and plotted 
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The peaks generated indicate fitted interatomic vectors in a unit cell and thus reveal information 
about distances between atoms. 
Patterson maps cannot be used to solve the phases of protein molecule, for the amount of atoms is 
large in proteins, but it can be applied to identify substructural position of heavy atoms, locate 
anomalous scatterers and orientate the molecular model in molecular replacement. Software like 
SOLVE (Terwilliger and Berendzen 1999) (http://solve.lanl.gov/) is based on Patterson 
function.(Rupp 2010) 
Since molecules with the same orientation and different positions in the unit cell have the same 
Patterson map, a trial-and-error method can help to determine best orientation of model for the 
new protein (Tickle and Driessen 1996). 
After the relative orientation of unknown protein was determined, this information is used to 
obtain the position of noncrystallographic operators related to crystallographic symmetry in the 
unit cell. The Patterson functions of intermolecular vectors are calculated to find the translation 
vectors of unknown structure. Finally, the initial phase is improved by extension from low 
resolution to high resolution (Rossmann 1990). 
3. Experimental Phasing 
Experimental phasing is to obtain phase information from the intensity information collected 
during x-ray diffraction experiment. 
a. Marker Atom Substructure Methods 
The first step of solving protein structure without any prior structure information involves 
determination of marker atoms substructure positions. Marker atoms covalently bond to protein 
molecule produce electronic difference map and thus generate initial protein phases. It is 




b. Isomorphous Replacement 
Isomorphous replacement is a method to simplify the structure solving by introducing a set of 
strong diffractors called heavy atoms, and locating them in a unit cell before solving the structure 
of entire protein. Two types of crystals are used. One is the native crystal and the other is the 
derivative crystal. A derivative crystal contains heavy atoms introduced by heavy metal ions 
soaking. The reflections from derivative crystal are the sum of those from native crystal and those 
from heavy atoms. 
Assuming the crystal lattice remains the same after heavy atom soaking, the reflection from 
derivative crystal FHP is made up by the reflection from heavy atom FH and that from native 
crystal FP. 
 𝐅HP = 𝐅H + 𝐅P 
 
(2.20) 
The intensity difference between native crystal and derivative crystal is generated by subtraction 
of those two (Figure 2-10), and used to compute both the amplitudes and phases of structure 
factor of heavy atoms FH via difference Patterson function or direct method (Rupp 2010). 
 
Figure 2-10: The complex structure factors of native crystal and derivative crystal with length 




FH provides phase information to solve FP. However, single isomorphous replacement (SIR) using 
only one heavy atom has ambiguity of obtaining two phase angles. If we use a Harker diagram to 
graphically represent the phase equation as in Figure 2-11, the two solutions are indicated by 
orange arrows. 
 
Figure 2-11: Harker diagram of SIR. 
In this case, we need to introduce a second derivative for multiple isomorphous replacement 





Figure 2-12: Harker diagram of MIR. 
c. Anomalous Scattering 
Anomalous scattering is the phenomenon that heavy atoms absorb x-ray anisotropically. It results 
in unsymmetrical reflection. 
Friedel pairs are centrosymmetric structure pairs with the same magnitude and opposed phase 
angle. 
 𝐅𝐡 = |𝐹ℎ|(cos 𝜑ℎ + 𝑖 sin 𝜑ℎ) = 𝐴ℎ + 𝑖𝐵ℎ 
𝐅−𝐡 = |𝐹ℎ|(cos(−𝜑ℎ) + 𝑖 sin(−𝜑ℎ)) = |𝐹ℎ|(cos 𝜑ℎ − 𝑖 sin 𝜑ℎ) = 𝐴ℎ − 𝑖𝐵ℎ 
(2.21) 
However, in the presence of heavy elements, which exerts a strong attraction to inner shell 
electrons, the ratio of inelastic scattering increases. The intensity obtains a real component f′ 
while the phase gains an imaginary component f″.  
The entire scattering is described with the following equation (Rupp 2010) 






Figure 2-11 Example of Se f′ and f″ curves. f′ is the real anomalous scattering contribution and f″ 
is the imaginary anomalous scattering contribution. The sharp jump in the f″ curve indicates 
absorption edge of Se element. Copied from http://www.bmsc.washington.edu/scatter/.   
f′ is the Karmers-Kronig transformation of normalized x-ray edge scan and  f″ is proportional to 
atomic absorption coefficient µ. Both can be obtained directly from the experiment. 
This generated anomalous difference, consisting the introduced real component Fa(𝑓0 + 𝑓′) and 





Figure 2-12: The scattering contribution from an anomalous scatterer in a matrix of normal 
scatterers. Copied from http://www.xtal.iqfr.csic.es/Cristalografia/parte_07-en.html. 
The magnitudes of Fa and Fa″ are dependent on the scattering element and the phases of them are 
relied on the position of the heavy atom. After obtaining the heavy atom positions by Patterson 
method and calculating phases, the Fa and Fa″ are used to solve the structure factors of protein. 
d. MAD/SAD 
Multiwavelength anomalous diffraction (MAD) is the method to collect data at multiple 
wavelengths to obtain maximum information from the same heavy atom derivative crystal. 
Absorption edge is a function of an atom in which its x-ray absorption ability drops significantly 
at the wavelength just below its characteristic emission wavelength Kβ, caused by excited electron 
departure.  
If the anomalous differences are strong enough when the data set is collected at the wavelength of 




diffraction (SAD). In other cases, we collect three sets of data adjusting the x-ray to different 
wavelengths (Figure 2-13): one peak data set at the f″ peak has the maximum anomalous 
contribution thus create an intensity difference; one inflection data set at the f′ negative peak to 
generate maximum dispersive difference when comparing to the remote data; and one remote 
data set at a high energy wavelength around 200 eV above the absorption edge. This multi-
wavelength anomalous diffraction (MAD) is used to obtain as much information as possible 
(Giacovazzo and Siliqi 2004). 
 
Figure 2-13: Choice of wavelengths for anomalous data collection. (Rupp 2010) 
e. Direct Method 





 𝛼−ℎ + 𝛼ℎ′ + 𝛼ℎ−ℎ′ ≅ 0 
 
(2.18) 
Thus, the tangent formula 
 
tan 𝛼h =
< 𝐸h′𝐸h−h′ sin(𝛼h′ + 𝛼h−h′) >h′




shows once the phases of some reflections are known, the phases of other reflections can be 
deduced by bootstrapping (Taylor 2010). The Direct method is usually used to determine the 
structure of small molecules at atomic resolution (<1.2 Å), or find the heavy atoms in derivative 
crystals using programs like SHELXD (Schneider and Sheldrick 2002) ( http://shelx.uni-
ac.gwdg.de/SHELX). 
 
H. Model Building and Refinement 
Model building is to construct an atomic structure model that fits into the electron density. 
Refinement is to match observed and calculated intensities by shifting atomic parameters. They 
are performed tightly and repeatedly if necessary.  
1. Model Building 
     After phasing calculation, an interpretable electron density map is produced. Next step is the 
model building, which is building the backbone of amino acid and fitting it to the electron density 
map.  
When resolution is high, model building is easy for the side chains are so distinctly present. 




Several softwares, such as ARP/wARP (http://www.embl-hamburg.de/ARP/) (Langer, Cohen et 
al. 2008) and RESOLVE (https://solve.lanl.gov/) (Terwilliger and Berendzen 1999, Terwilliger 
2000), could serve the auto-building if the resolution of electron density map is good enough.  
During manual model building, Cα-atoms are put at the side chain branching point as a start, 
followed by placing distinct amino acids like tryptophan and phenylalanine as well as di-sulfade 
bonds into the electron density map. Secondary structure of the protein is normally predicted to 
assist building and typical helixes or sheets backbone is easily discerned and located in the 
electron density map. As for these unconnected secondary structures, heavy atoms are used as 
markers to identify the exact sequences of the helix or sheet. In addition, amino acids with large 
side chains, such as trypophan, tyrosine or lysine are also used as markers.    
At this stage, those amino acids with unclear side chain are designated as alanines. The basic 
principle during the first crude model building is to only assign amino acids based on electron 
density map, without introducing error to the model.  Next, this crude model is used in 
combination with original native intensity to calculate structure factors and the phases. This step 
will generate a clearer map, which is used for further map improvement.  
2. Refinement 
Refinement is to adjust the parameters describing a model in order to fit them with experimental 
observations. But we have more experimental data points (n) available than model parameters (p). 
In order to increase data-to-parameter ratio, besides reflections data, the stereochemical restraints 
are included such as bond lengths, bond angles, planarity and torsion angles to increase the 




The R factor is used to describe difference between the calculated structure from model and 
observed native structure factor. It indicates how well the model is superimposed with the real 








After iterative improvement of maps and models, the R factor could be lowered to less than 30%. 




Before we certify a structure as ‘a decent structure’, several validations need to be taken into 
consideration. 
Rfree is the R factor of a set of reflections not used in refinement and Rwork is the R factor of the set 
of reflections used in refinement. If a refinement improves Rfree as well as Rwork, it qualifies a 
good refinement. 
A commonly allowable difference between Rwork and Rfree is less than 5%, and Rwork being 1/10 of 
the resolution. For example, a 2.2A resolution dataset may have a Rwork around 22%. 
The Ramachandran plot is a diagram displaying the torsion angles ψ and ϕ of peptide bond 
between non-glycine amino acids (Figure 2-14). It defines three regions of possible backbone 
conformations that amino acids forming α helix, β sheet and turns would fall into, and a 





Figure 2-14: A Ramachandran plot showing possible ψ and ϕ values of α helix and β sheet. 
Copied from http://swissmodel.expasy.org/course/text/chapter1.htm. 
Geometry root mean squate deviation (RMSD) of bond length and bond angle is computed and 
should be less than 0.01 and 1, accordingly. 
Amino acid side chain rotamer conformation is taken into consideration when multiple positions 
are present with individual occupancy. 
Structure is examined at any close contacts to identify whether the contact is rational or not.  
Servers like Molprobity (http://molprobity.biochem.duke.edu/)(Chen, Arendall et al. 2010) are 










Leucine-rich repeat kinase 2 (LRRK2) is a multi-domain protein expressed widely in organs 
including brain, heart and liver. Mutations of LRRK2 are largely found in patients of Parkinson’s 
disease, an age-related neurodegenerative disease affecting six million people around the world. 
A major part of pathological mutations are located in the central part of LRRK2, containing a Ras 
of Complex (ROC) GTPase domain, a kinase domain and a domain between them called C-
terminal of Roc (COR) domain. Previous research has provided evidence that the Roc domain 
regulates kinase activity as a binary switch through a GTP/GDP bound cycle. The structure of the 
inactivated Roc has been solved previously in our lab and we propose to determine the structure 
of ROC in the activated state. The expected results would reveal the dynamic conformational 
changes in the ROC GTPase domain, providing important clues on the mechanisms of GTP 
hydrolysis and signaling.  
1. Parkinson’s disease 
Parkinson’s disease (PD) is a common age-related neurodegenerative disease.  
PD is the most commonly observed movement disorder. The physical symptoms of PD include 




over the world (Goedert 2001). Its demographics vary among age groups, increasing significantly 
along with age. PD affects 17.4 out of 100 000 person from 50 to 59 years old and 93.1 out of 
100, 000 person years from 70 to 79 years old (Bower, Maraganore et al. 1999). 
PD is a progressive bradykinetic disorder. The pathological phenotype of PD is severe loss of 
dopaminergic neuromelanin-containing neuronal cells in the pars compacta of substantia nigra in 
the midbrain, as well as protein aggregation enriched with α-synuclein in three intraneuronal 
inclusions in the surviving neurons: the Lewy body, the pale body and the Lewy neurite (Hassler 
1938). The loss of dopamine causes motor abnormality in PD patients.   
 
Figure 3- 2: Normal and diminished substantia nigra in PD. Copied from A.D.A.M. 2011. 
Most PD cases are sporadic and idiopathic, while few are possibly implicated by environmental 
factors. For example, researchers found out toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MTPT) induces parkinsonism (Langston, Ballard et al. 1983). Genetic factors were found to also 
play a role, since mutations in LRRK2 and α-synuclein genes were found in both familial and 





Although therapeutic treatments targeting individual psychological symptoms of PD have been 
developed through clinical study (Lees, Hardy et al. 2009), none of them is able to stop the 
undergoing neurodegenerative process.  
2. LRRK2 
Recent genetic research has revealed some connection between the leucine rich repeat kinase 2 
(LRRK2) and PD. Mutations of LRRK2 being largely identified in both familial and sporadic PD 
made the protein a promising pharmaceutical target against PD (Aasly, Toft et al. 2005). 
LRRK2 is a multidomain protein which forms a functional dimer. 
Through genome-wide association study, the gene LRRK2 encoding a 2527 residues. protein was 
identified as one of the most likely susceptibility causative genes for autosomal dominant 
Parkinsonism  (Satake, Nakabayashi et al. 2009).  
LRRK2 belongs to the ROCO protein family and contains six domains. As seen in Figure 3-2, 
LRRK2 contains an ankyrin repeats domain, a leucine-rich repeats (LRR) domain, a Ras of 
complex (Roc) domain, a carboxy-terminal of Roc (COR) domain, a (serine/threonine) kinase 
domain and a WD40 domain. Most pathogenic mutations are located in the three central domains: 
Roc, COR and kinase domain, for example, R1441C, R1441G, R1441H in the Roc domain, 
Y1699C in the COR domain and G2019S and I2020T in the kinase domain. (Cookson 2010) 
LRRK2 requires dimerization through several interfaces across the protein to be kinase-active 
(Greggio, Zambrano et al. 2008), indicating it regulates its own function. The portion of 
dimerization dependents on kinase activity, which might further be related to pathology (Sen, 





Figure 3-2: Scheme of the domain architecture of LRRK2. LRRK2 dimerizes through several 
interface. Functions and some important pathogenic mutations are indicated (Cookson 2010). 
3. Roc domain 
Roc GTPase domain regulates kinase activity and LRRK2 toxicity. 
The Roc domain is an authentic GTPase. It binds and hydrolyzes GTP (Deng, Lewis et al. 2008).  
Mutation in the ROC domain abolished its GTP binding ability, and also incapacitated the kinase 
activity of LRRK2, indicating that the GTPase activity of ROC domain regulates the kinase 
activity  (Ito, Okai et al. 2007). GTP hydrolysis is also required for normal kinase activity, and 
furthermore controls the LRRK2-induced inhibition of neurite outgrowth in neuron cell (Biosa, 
Trancikova et al. 2013).  
The COR domain is a constitutive tandem domain to ROC in all ROCO superfamily members 




mitogen-activated protein kinase kinase kinase (MAPKKK) (Marin 2006), which is proved to 
autophosphorylates LRRK2 in the Roc domain (T1343 and T1491) (Greggio, Taymans et al. 
2009).  
Some mutations in Roc or COR decreasing GTPase activity and mutations in kinase domain 
increasing kinase activity cause the same Parkinson symptoms, probably because they evoke 
similar downstream signaling changes (Cookson 2010). Evidence showed that the kinase activity 
of LRRK2 is stimulated upon ROC binding GTP (Ito, Okai et al. 2007) and mutations preventing 
GTP binding decreases kinase activity (Ito, Okai et al. 2007, Lewis, Greggio et al. 2007) . 
Mutated LRRK2 with reduced kinase activity also reduces neuron toxicity (Smith, Pei et al. 
2006). 
Overall, the Roc domain and the kinase domain work together with autoregulatory 
interdependence. Although the mechanism how these domains of LRRK2 regulate each other and 
effect downstream signal pathway and why it becomes pathogenic remains unclear, a hypothesis 
is that LRRK2 actively mediates downstream signaling pathway while binding GTP, perhaps by 
increasing the affinity to some unknown partner (Cookson 2010). Roc GTPase activity might be 
decreased upon phosphorylation. Thus, Roc-bound GTP might stimulate downstream pathways in 
a feed-forward loop, and the GDP- or GTP-bound states of Roc might indicate whether LRRK2 is 
pathogenic. This hypothesis is supported by some studies showing kinase-dead or GTP-binding-
deficient mutants are less toxic than wild type (Greggio, Jain et al. 2006). 
The Structure of ROC domain 
The high resolution structure of Roc domain in complex with GDP and Mg2+ was determined 
previously in our lab (Deng, Lewis et al. 2008). Roc appeared to be a dimer in the crystal as a 
functional unit with extensive domain swapping in a head-to-tail fashion. The GDP Mg2+ binding 




mutations are pathologically related and increase kinase activity, are located at the dimer 
interface. It is possible that the mutations (R1441C and I1371V) would destabilize the dimer as a 
functional unit and further decrease the kinase activity. There are five α-helices and six β-strands 
in a monomer, and the loop between the second α-helix and the second β-strand (G2 loop, also 
known as switch I) is disordered (indicated in Figure 3-3), as well as the one between the second 
β-strand and the third β-strand. The switch I loop was shown to have significant conformational 
change upon binding GTP and GDP throughout GTPase families (Paduch, Jelen et al. 2001). 
Switch I and switch II regions are conserved loops throughout the Ras GTPase family. They 
locate around the active site and facilitate GTP hydrolysis (Vetter and Wittinghofer 2001). It is 
possible that in ROC, switch I and switch II undergo conformational changes upon binding GTP, 
and during the GTP/GDP binding cycle, the conformational changes might be delivered to the 
kinase domain through the COR domain. 
 
Figure 3-3: The crystal structure of a monomer of Roc. The 5 α-helices and 6 β-strands are 




In summary, LRRK2 is a protein that might serve as a crucial target for the treatment of 
Parkinson’s disease, and the GDP- or the GTP-bound states of the Roc domain might regulate the 
kinase domain. The structure of the inactivated state (GDP-bound) has already been solved, and 
we are interested in solving the activated state, for the comparison of inactivated state and 
activated state provides information regarding the mechanism of Roc GTP hydrolysis and 
signaling. 
4. Prokaryotic Roc-Cor Domain 
Studies on Clorobium tepidum LRRK2 showed that ligand binding induced significant change in 
the Roc-Cor tandem. The result of trypsin digestion of C. tepidum LRRK2 indicated that the 
GppNp (a nonhydrolysable GTP analog) binding Roc-Cor tandem was quite resistant to 
digestion, whereas the nucleotide-free Roc-Cor tandem was brokendown to the Cor domain.  
The crystal structure of the Cor domain was solved. It contains two subdomains connected by a 
long linker. The N-terminal subdomain was mainly made up of α-helices, while the C-terminal 
subdomain contains seven-strand antiparallel β-sheets and a β-hairpin motif. Mutations on the 
dimer interface and gel filtration analysis demonstrated that two Cor molecules dimerize through 
their C terminal subdomain.  
The nucleotide-free C. tepidum Roc-Cor mutant crystallized and the structure is shown in Figure 
III-4. The Cor domains dimerize through its C-terminal subdomain, while the two attached Roc 
domains are positioned apart. Only one Roc was visible in an asymmetric unit (RocA). The 





Figure 3-4: The crystal structure of C. tepidum Roc-Cor tandem. 
Human LRRK2 and C. tepidum LRRK2 appear to be different in many aspects. The C.tepidum 
Roco has a much higher affinity for GTP than GDP (Gotthardt, Weyand et al. 2008), but human 
Roc has higher affinity for GDP (Li, Dunn et al. 2009). Also, C. tepidum Roc-COR dimerizes 
through its C terminal subdomain of Cor (Gotthardt, Weyand et al. 2008), while human Roc 
dimerizes through domain swapping (Deng, Lewis et al. 2008). Furthermore, the Roc domain in 
the C. tepidum Roco is a monomer displaying canonical Ras GTPase (Gotthardt, Weyand et al. 
2008), but the human Roc domain is dimer adopting head-to-tail fashion, with catalytic site 
contributed by both protomers of dimer (Deng, Lewis et al. 2008).So our goal is to solve the 
structures of domains in human LRRK2. 
With a lot of structure and function of LRRK2 remaining unknown, we propose to determine the 
structures of activated human Roc and Roc-Cor tandem domains. The superimposed GDP and 
GTP bound Roc domain will provide some detailed understanding of the structural change in the 
Roc, and the Roc-Cor tandem structure, and will provide some information about how GTPase 
activity change passes to kinase domain through Cor domain as a molecular hinge. Together they 
may contribute to the understanding of the structure and function of LRRK2 and its role in the 







Figure 3-5: Projects flow chart. 
1. Roc Plus GTP Analog Crystallization 
a. Cloning and Purification 
Cloning and purification of Roc or its mutants were carried out as described in II.B. GDP or GTP 
analog was supplied from the 1st nickel elution. The samples collected along the purification of 





Figure 3-6: SDS-PAGE gel of samples along the Roc purification. The lanes from left to right 
indicate the marker, induced whole cell, cell lysate flown through Ni resin, TEV cleaved sample, 
Roc with N-terminal His tag eluted from Ni resin, TEV, TEV cleaved Roc, final Roc without His 
tag, uncleaved material eluted from Ni resin.  
b. Stability of Roc in complex with ligands 
Thermo-denaturation assay (thermo-melt) measures the temperature required for the folded 
protein to unfold (Tm) and thus indicates the stability of protein. The method is based on the 
character of fluorescence dye, such as SYPRO Orange fluorescence dye (Invitrogen) we used. 
SYPRO Orange is excited by light around wavelength 490 nm and emits fluorescence of 610 nm. 
When protein unfolds and hydrophobic regions of the protein are exposed to solvent, the 
fluorescence dye binds to them and becomes fluorescent, and Real Time PCR instrument was 
used to record fluorescence counts. Finally, the first derivative of fluorescence counts is 
calculated in Excel, and the temperature corresponding to the fastest change is the melting 
temperature (Tm).  
The differential scanning fluorimetry is widely used to screen compound versus protein, for the 




 The result of Thermo melt of Roc with various ligands is shown in the figure below (Figure III-
7).  Roc is not stable without any ligand and different ligands have different affinity to it, all of 
which increases the stability of Roc.  
In a recent paper, the affinity of Roc binding to GDP was measured with the KD being 0.47 μM. 
A nonhydrolysable GTP analog GTPγS was measured to estimate the approximate binding 
affinity between Roc and GTP. The KD is 7.85 μM (Liao, Wu et al. 2014). In combination with 
our Tm data, the binding affinity of all the ligands should be within the μM range. 
 
Figure 3-7: The first derivative of fluorescence reading of Roc in complex with various ligands. 
Melting temperatures are indicated above.  
Ligand Tm 
Mg 39ºC 
GDP 48 ºC 
GTP 42 ºC 
MANT-GDP 40 ºC 




68 36 ºC 
GppNp 39 ºC 
GppCp 36 ºC 
 
Table 1: Melting Temperature of Roc in complex with various ligands. 
c. Selecting proper ligand for crystallization  
Roc is an authentic GTPase and hydrolyzes GTP. When GTP was used in Roc purification and 
crystallization, GDP was observed in the structure (Deng, Lewis et al. 2008). So instead of GTP, 
we used two types of analogues: GDP plus aluminum tetrafluoride (AlF4-) and non-hydrolysable 
GTP. 
AlF4- has similar atomic size with PO43-, and it appears to activate G protein by binding the Gα 
subunit of heterotrimeric G protein in its GTP binding state, mimicking the ɤ phosphate of GTP 
(Bigay, Deterre et al. 1985). In the similar way, AlF4- is also commonly used in complex with 
GDP as a GTP analogue in crystallography (Tesmer, Berman et al.). Here we apply AlF4 and 
GDP together to Roc protein in order to simulate the transition state of Roc hydrolyzing GTP. 
We used two types of non-hydrolysable GTP analogs, GppNp (Sigma) and GppCp (Jena 
Bioscience).  
d. Roc in complex with GppNp  
Roc in complex with GppNp was purified as described in II.1.2. The complex was concentrated 





Seeding is a powerful method for crystal growth optimization. Crystals unqualified for data 
collection, such as small or twinned crystals, can be grinded finely in reservoir buffer and used as 
micro seeds. These seeds are introduced into pre-equilibrated supersaturated protein and reservoir 
buffer solution. In this way, we can control not only the number of nucleation sites in solution, 
but also the equilibration time before seed introduction (Bergfors 2007). Seeding has been proven 
to increase size of crystal reproducibility in many cases, but Roc-GppNp failed to be improved. 
e. Glutaldehyde cross-linking and soaking 
Roc with GDP crystalized in 2.1 M malic acid, but the structure showed that protein did not have 
ligand inside. It is understandable because the crystal grew in high salt condition. Strong ion 
strength would compete with the ligand binding and extrude it from the binding site. However, 
the binding pocket was open and empty, providing us the opportunity to soak the ligand back into 
the pocket.  
During soaking, we stepwisely exchanged the crystal containing reservoir buffer from 2.1 M 
malic acid to lower ion strength, for ligand cannot soak in under the high salt condition. The 
potential differences between inside and outside of crystal caused the crystal melting or crashing, 
so we used glutaraldehyde to crosslink crystal. 
Glutaraldehyde undertakes polymerization in alkaline condition and predominantly links the ɛ-
amino groups of lysine residues. It fixes the crystal lattice and facilitates the soaking of ligand 
when the potential in and out of crystal lattice is different. Crystals were transferred to reaction 
buffer containing 0.1 M HEPES, 0.12 M NaCl, 25% ethylene glycol and different concentrations 
of glutaraldehyde for cross-linking for various length of time, and the reaction was stopped by 
washing crystal twice with reservoir buffer to remove residual glutaraldehyde. (Wine, Cohen-




The crystal was then mounted in an in-house x-ray system to determine its diffraction ability. The 
original crystal diffracted 2.8 Ǻ in synchrotron x-ray source. Different concentration of 
glutaldehyde and various length of reaction time was tested. Using glutaraldehyde concentration 
higher than 1% or reaction time longer than 5 minutes caused the crystal to loose diffraction, so 
we put crystal in 1% glutaldehyde for 5 minutes and then transferred the crystal to buffer 
containing GDP plus AlF4- or GppNp, while lowering the malic acid concentration and increasing 
the PEG 8000 concentration stepwisely. The soaking lasted for 10 to 30 minutes to allow the 
ligand entering into crystal. 
This manipulated crystal diffracted 3.8 Ǻ in synchrotron x-ray source, showed a P212121 space 
group. There was no density in the GTP binding site. 
f. Site-direct Mutagenesis 
i. F1436 mutation 
According to the known structure, phenylalanine 1436 occupies the space of gamma phosphate, 
so we mutated this phenylalanine to alanine. 
 
Figure 3-8: The illustration of the F1436 (purple) and GDP (red) in Roc GDP structure. 





Site-directed mutagenesis was performed as described in IV.2.3. Forward and reverse primers 
containing desired mutation (F1436A or F1436 R) were ordered from Invitrogen. Two pairs of 
primers, 1333 forward and 1436 reverse, 1436 forward and 1516 reverse, were extended using 
original plasmid as template by PCR, generating 1333-1436 and 1436-1516 fragments 
accordingly.     
 
Figure 3-9: The DNA electrophoresis gel of mutated fragments ( 1333-1436 and 1436-1516 ). 
The two overlapping fragments were elongated by PCR using 1333 forward primer and 1516 
reverse primer. Then mutation containing fragments were digested with restriction enzymes and 
ligated to vector.  





Figure 3-10: The DNA electrophoresis gel of colony PCR products. Left to right: 3 colonies of 
F1436R mutation, 4 colonies of F1436A mutation, marker. 
F1436A and F1436R were expressed in 2L cells each, and purified in complex with GDP. 
                             F1436A                                                                     F1436R 
 
Figure 3-11: SDS-PAGE gels of samples collected along F1436A (left gel) and F1436R (right 
gel) purification. From left to right: marker, non-induced whole cell, induced whole cell, cell 
pallet, flow-through from nickel resin, elution from nickel column, TEV, mixture after TEV 
digestion, flow through from the second nickel resin (concentrated for crystallization setting up), 
elution from the second nickel resin. 
1:10 ratio of fresh AlCl3 and NaF were put into protein solution before crystallization screening. 




Grid screening optimization 
1436A mutant crystallized in 0.2 M lithium sulfate, O.1 M Bis-Tris, pH 6.5, 25% PEG 3350, so 
grid screening buffers varying pH from 5.5 to 7.0 as well as PEG 3350 concentration from 20% 
to 35% was prepared and used as reservoir buffer.  
After overnight incubation, needle shaped crystal grew from pH 6.5, 30% PEG 3350, pH 7, 30% 
PEG 3350 and pH7, 35% PEG 3350. But their size did not improve after runs of optimization. 
ii. Surface entropy reduction 
Wild type ROC was crystallized with GDP, but we failed to obtain the crystal with non-
hydrolysable GTP or with GDP and AlF4-. Because surface glutamic acid and lysine might 
prevent crystallization, due to their long flexible side chains that prevent favorable lattice contacts 
(Derewenda and Vekilov 2006), we mutated three patches of glutamic acid or lysine (shown in 
Figure III-17) to alanine as an approach to reduce surface entropy, which could potentially 





Figure 3-12: The illustration of 3 patches of surface mutation. Patch 1: 1459E/A, 1460K/A, 1463 
K/A; Patch 2: 1471K/A, 1476K/A; Patch 3: 1495 D/A, 1499K/A, 1502 K/A 
Based on the F1436A mutant, we constructed P1, P2, P3 and P1+2, P1+3, P2+3 mutants 
containing corresponding patches of mutations. Site-directed mutagenesis and purification were 
performed as described above. 
 
Figure 3-13: SDS-PAGE gel of samples collected along P3 purification. From left to right: 
induced whole cell, cell pallet, flow-through from nickel resin, elution from nickel resin, marker, 
mixture after TEV digestion, elution from the second nickel resin, flow through from the second 





Figure 3-14: SDS-PAGE gel of samples collected along P1+3 purification. From left to right: 
marker, non-induced whole cell, induced whole cell, cell pallet, flow-through from nickel resin, 
elution from nickel resin, mixture after TEV digestion, elution from the second nickel resin, flow 
through from the second nickel resin (concentrated for crystallization setting up.) 
g. We have obtained two different crystal forms of Roc with AlF4 in the crystallization 
condition. 
Previous GDP-bound Roc has thin rhombus plate morphology, but with the presence of AlF4-, 
P1+3 mutant formed hexagon plate crystals and P3 mutant formed di-pentagonal pyramid 
crystals.  
 





Figure 3-16: P3 di-pentagonal pyramid crystals. Space group is P32. 
Data collection and initial processing is described as in II.5. The P1+3 hexagon crystal diffracted 
to 1.8 Ǻ but the di-pentagonal crystal only diffracted to 3.6 Ǻ.  
Since a highly similar structure, is already present, we applied molecular replacement to initial 
data using Roc GDP complex structure as the model and obtain the initial phasing by using the 
Phaser program (Read 2001) and further modeling was carried using COOT (Emsley and Cowtan 
2004). Finally structure was refined using REFMAC (Murshudov, Vagin et al. 1997). In the 





Figure 3-17: The electron density map of binding pocked of P1+3 in complex with GDP AlF4- 
crystal. We can observe the electron density for GDP and Mg2+ but no AlF4- . Drawn by coot 




Table 1 Roc P1+3-GDP-AlF4 crystal   
Statistics of data collection. 













† Rsym =  |Iobs – Iavg|/  Iavg.  
  
Data collection  
Beamline 19-ID, APS 
Wavelength (Å) 0.97918 
Space group C2 
Unit-Cell parameters a = 70.0 Å, b = 52.9 Å,c 
= 106.8 Å, α=90.0°, 
β=108.2°, γ=90.0° 
 
Resolution (Å) 50 – 1.8 
Total reflections 166,596 
Unique reflections 35,627 
Rsym (%)† 12.5 (81.9) 
Redundancy 4.7(3.6)  
Completeness (%) 99.7 (98.4) 





h. We obtained crystal of Roc in the presence of GppNp. 
Roc mutant 75 was the combination of F1436R and P3 mutations. It was purified in complex with 
GppNp and concentrated to 13.2 mg/ml. It crystalized in the condition of 0.2 M sodium acetate, 
0.1 M sodium cacodylate pH=7.25, 25% PEG 8000. The data collection, processing and structure 
determination was carried out as above. In the binding site, GDP was observed instead of GppNp. 
 
Figure 3-18: The electron density map of the binding pocket of mutant 75 in complex with 
GppNp crystal. We can observe the electron density for GDP and Mg2+ but no GppNp. Drawn by 





Table 2 Roc 75-GppNp crystal   
Statistics of data collection. 













† Rsym =  |Iobs – Iavg|/  Iavg. 
  
Data collection  
Beamline 19-ID, APS 
Wavelength (Å) 0.97915 
Space group P1 
Unit-Cell parameters a = 44.1 Å, b = 44.0,c 
= 103.00 Å, α=97.3°, 
β=98.6°, γ=101.2° 
 
Resolution (Å) 50 – 1.9 
Total reflections 103,723 
Unique reflections 53,050 
Rsym (%)† 5.5 (20.9) 
Redundancy 2.6(2.1)  
Completeness (%) 91.0 (30.2) 





2. Roc-COR domain crystallization 
a. SUMO Tagged Roc-COR Cloning and Purification 
i. Cloning 
We selected four Roc-COR fragments of different length, amplified them with KOD enzyme 
(Invitrogen), then digested the fragments and pSUMO vector with the same restriction enzymes 
(Nde I and BamH I) at both ends. 
 
Figure 3-19: The DNA electrophoresis gels showing amplified Roc-COR fragment (1333-1579) 
(left gel) and the double digested vector and fragment (right gel). 
Vector and amplified fragment were ligated by T4 ligase and thus transformed into E. Coli cell 
electronically.  




Colony PCR was performed first. After transformed competent cells growing on a Kanamycin 
resistant LB agar plate for overnight, a single colony was picked from the plate and grown in LB 
medium until dense. Plasmid was subsequently extracted from colony and used as template to 
amplify the DNA fragment between two primers (1333 or 1310 Nde I and 1579 or 1633 BamH I) 
at both ends. PCR product was analyzed with DNA gel electrophoresis to make sure the insertion 
should contain one and only one band with corresponding molecular weight (Figure 3-20). 
 
Figure 3-20: The DNA electrophoresis gel of colony PCR results of 4 constructs (3 clones from 
each construct). Upper left: 1333-1677. Upper right: 1310-1633. Lower left: 1333-1579. Lower 
right: 1333-1633. 
The extracted plasmids was sent for sequencing with T7 forward and reverse primers and the 
result was aligned with correct sequence using BLASTP program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&PAGE_TYPE=BlastSearch&LINK_
LOC=blasthome) to confirm the insertions were correct. 




For each construct of Roc-COR cloned, 50 ml cell culture was grown and lysed. Expressed 
proteins were purified through affinity tag with nickel resin. Samples were collected along 
purification and analyzed with SDS-PAGE gel. 
Only 1333-1579 construct was able to be expressed and be purified in solution. (Figure 3-21) 
  
Figure 3-21: SDS-PAGE gels showing samples from small scale expression and purification of 
four constructs. From left to right: marker; non induced whole cell; induced whole cell; cell 
pallet; elution from nickel resin. 
iv. Large Scale Purification 
Protein from 2 liters of cell culture expression was purified through affinity tag, but the quality of 





Figure 3-22: The SDS-PAGE gels of samples showing two batches of 1333-1579 construct 
purification. Left gel (batch 1) from left to right: marker, non-induced whole cell, induced whole 
cell, cell pallet, flow through nickel resin, the 1st, 2nd and 3rd elution fraction from nickel resin, 
supernatant after TEV digestion, precipitation after TEV digestion. Right gel (batch 2): marker, 
mixture before TEV digestion, mixture after TEV digestion, the concentrated 2nd nickel purified 
protein in batch 1, the concentrated 2nd nickel purified protein in batch 2, the three fraction from 
2nd nickel elution. 
v. Crystallization 
Multiple methods were applied in order to increase the purity of Roc-COR protein, such as 
detergent wash, GroEL/GroES chaperone assistance, but none of them was effective. The protein 
was used for crystallization screening anyway but no crystal was observed. 
b. 1333-1579 C Terminal His-tagged Roc-COR Purification 
The 1333-1579 fragment with permanent C-terminal His tag was cloned in the same way as 
described above. It could be expressed and purified, but the sample contained two adjacent bands 
which could not be separated even by size exclusion column. Western blot using anti-His 
antibody identified the upper band to be His-tag containing protein (Figure III-23) (Figure III-24). 
Calculated from retention volume the molecular mass of particles in the peak was 47.7 kDa and 
its real molecular mass is 28.4 kDa. The protein might be heterodimer in solution containing one 
intact protomer and the other degraded slightly from the C terminus. The sample was used for 






Figure 3-23: The size exclusion chromatograph of Roc-COR 1333-1579, the SDS-PAGE gel 









1. The Information Obtained from Results 
I obtained four Roc crystals in the presence of GTP analogs. One from glutaldehyde crosslinking 
and soaking had no GTP bound. In the structure of crystal of mutants in complex with GDP and 
AlF4-, only GDP was present. In the structure of crystal grew from Roc mutant purified in 
complex with GppNp, GDP was binding in the active site instead of GppNp. 
2. Why I Didn’t Obtain Roc-Cor or Roc GppNp Structure 
The reason why we were not able to obtain the Roc-Cor tandem crystal might be that the linker 
between Roc domain and Cor domain is very flexible, thus the Roc-Cor tandem is mobile. In the 
prokaryotic Roc-Cor tandem structure, one Roc domain of the dimer was fixed by crystal lattice 
contact by neighboring molecule, while the other one was so mobile that it was invisible in the 
crystal structure (Gotthardt, Weyand et al. 2008). If human Roc-Cor tandem is elastic too, it will 




The reason why only GDP was present in binding pocked instead of GppNp might be that GDP 
has higher affinity to Roc than GppNp (Liao, Wu et al. 2014), and the GDP was probably carried 
along from E. coli. Other literature about GTPase GppNp complex suggested thoroughly 
degrading GDP by alkaline phosphatase before putting GppNp into GTPase (Ye, Shima et al. 
2005), but Roc is quite unstable without ligand bound so we cannot apply this method. 
3. Surmises and Future Direction 
To predict the structure of GppNp bound state of Roc, we need to take a look into Ras GTPase. It 
is consistent throughout Ras family that, the structural change of hydrolyzing GTP is described 
like loaded spring. The releasing of ɤ-phosphate causes switch I and switch II region to relax into 
GDP bound state (Vetter and Wittinghofer 2001).             
The structures of Ras GppNp and GDP bound state superimpose well and their difference mainly 
exists in switch I and switch II region (Vetter and Wittinghofer 2001). When overlapping the 
cartoon structures of GDP and GppNp bound m-Ras (shown in Figure 3-25), the major change 
between them is present in the two switch regions. The switch II is disordered because it was 





Figure 3-25: The comparison of GDP and GppNp bound m-Ras structure. The GDP bound m-Ras 
(gray) has its GDP and Mg2+ colored in dark blue and switch I and switch II region colored in 
blue. The GppNp bound m-Ras (pink) has its GppNp and Mg2+ colored in mauve and switch I 
and switch II region colored in hot pink. A part of switch II region is disordered (dotted line). 
Since the GTP-bound state of Ras structures are relatively similar (Vetter and Wittinghofer 2001), 
we can reasonably surmise the GTP-bound Roc adopt the similar switch I and switch II 
conformational change. 
The comparison between Roc and m-Ras also shed some light on the pathologically associated 
mutations in Roc. When Roc is aligned to m-Ras, its PD-related mutant R1441 corresponds to 
V113 in m-Ras. This Val interacts with α-helix connecting switch II region in GTP bound form. 
R1441 in Roc might adopt the similar function. Mutation in this position might cause the 





Figure 3-26: The superimposed Roc (teal) and m-Ras (pink). The R1441 and the V113 are 
highlighted in darker color and labeled. 
The only available model for Roc-COR tandem is the prokaryotic C. tepidum Roco. Despite of 
the low similarity between bacterial and human LRRK2, we can still get some clue of 
pathological mutation Y1699C in Cor domain information from the prokaryotic structure. The 
conserved Y1699 is Y804 in C. tepidum Roco, which contacts with the α-helix connecting switch 
II (Gotthardt, Weyand et al. 2008). It is possible that Y1699 in human COR domain sits in the 
Roc/COR interface and interacts with Roc domain, the mutation of which decreases GTPase 
activity. 
Roc domain is also a potential target for drug design. Inhibitors binding Roc domain might 










A6 is a vaccinia virus protein expressed after virion gene replication and is packed tightly to the 
virion core. A6 is essential for poxvirus assembly and it was suggested to be involved in vaccinia 
virus morphogenesis by recruiting membrane as well as other important proteins from the 
infected cell to virion factories. Although the sequence of A6 is highly conserved through all 
vertebrate poxvirus (Meng, Embry et al. 2007), there are no known homologs outside the 
poxvirus family to suggest its function. Here we propose to reveal the structure of A6 by x-ray 
crystallography to obtain insights into its function. We hypothesize that certain functional 
domains of A6 share similar structures with a protein of known function. Therefore, searching 
through the structure database with the structure of A6 may provide us important clues about its 
function and mechanism. 
1. Poxvirus 
Poxvirus is a large, enveloped, double stranded DNA virus containing a complex genome varying 
from 130 to 230 kbp. Unlike other DNA viruses that release their genome upon contacting the 




themselves in the nucleus, poxvirus releases and replicates its DNA in the cytosome (Moss 2001). 
Thus, poxvirus requires genes encoding for proteins and enzymes used for transcription and 
translation (Moss 2013).  
Research on poxvirus morphogenesis proteins draw our attention, because they might not only 
expand our knowledge on how poxvirus interacts with host cytosolic organelles and mediates its 
replication, but also shed light on the mechanism of cell regulation.  
2. Replication Steps 
As shown in Figure IV-1, the replication of poxvirus involves six steps.  
It starts with the entry of virion particle into the infected cell (step 1), either upon binding 
unknown receptors or through endocytosis. Uncoated and exposed viral core particles go through 
early transcription and translation to produce the immunomodulatory proteins, enzymes, 
replication factors and translation factors (step 2). Then, the viral core particles are translocated to 
the outside of cell nucleus, and the nucleoprotein complex containing viral genome are released 
(step 3). The viral genome is replicated in certain domains of the infected cell called “factories” 
surrounded by ER derived cisternae where cell organelles are excluded. The genome is replicated 
as a concatemer and transcription factors are transcribed and translated, as well as enzymes and 
structural proteins (step 4). Then concatemer genome is resolved into linear double stranded DNA 
and packed with certain late viral proteins (A6 being one of them) into the immature virions (IVs) 
(step 5). How IVs mature into intracellular mature virions (IMV) remains unknown, with possible 
involvement of Golgi apparatus (step 6). After that IMVs are released in three ways. Most of 
virons are released through cell lysis and remain IMVs. Other virions bud through cell membrane 
and pick up viral envelope from plasma membrane of the inffected cell. Among them, cell-




(probably microtubules) into contact with a second cell, and extracellular enveloped virions 
(EEVs) are simply released from the infected cell. 
 
Figure 4-1: The illustration of poxvirus replication. A6 is one of the late proteins translated as 
indicated by the red arrow.(McFadden 2005) 




Vaccinia virus is the most intensively studied member of poxvirus viruses. It has linear, double 
stranded DNA around 190 kbp. The large genome contains genes encoding proteins responsible 
for cytoplasmic viral DNA replication and transcription.  
Unlike the lethal variola virus (small pox), the most notorious member of the poxvirus family, 
vaccinia virus causes only minor symptoms, while it can stimulate immunogenic response against 
the lethal smallpox. Therefore, a benign form of vaccinia virus is the major active component of 
the vaccine against small pox. With cytoplasmic replication site being the target for foreign gene 
introduction, the ability to infect many different cell lines, and its unique cytoplasmic 
transcriptional and translational apparatus, vaccinia virus can therefore serve as a vector carrying 
new genes to generate recombinant vaccines against other infectious diseases (Hruby 1990). 
Under electron microscope, vaccinia viruses during replication go through morphological 
changes from double-layered crescents to closed-circle IVs, then to electron-dense nucleoid 
containing IVNs, and sequentially to membrane protein surrounded elliptic MVs. Lipid 
membrane wrapped viruses (WVs) are observed as final stage of viruses before released from 





Figure 4-2: The illustration of poxvirus morphology development. (Condit, Moussatche et al. 
2006). IV: immature virion. IVN: immature virion with nucleus. MV: mature virion. WV: 
wrapped virus. EV: extracellular virus. 
4. The Importance of A6 
Poxvirus genome contains 218 open reading frames, 91 of which are conserved through all 
vertebrate poxvirus species (Upton, Slack et al. 2003). Vaccinia virus A6 is encoded by one of 
those genes. A6 protein was identified by gel-free liquid chromatography and tandem mass 
spectroscopy of whole virions (Chung, Chen et al. 2006). 
A6 contains 372 amino acids in total. Its molecular weight is around 43 kD and its calculated pI is 
8.8. It has no homolog outside the poxvirus family, and no homologous structure is available to 
date. 
A6 is expressed after viron replication and then packed tightly in the virion core. Although the 




on epitope-tagged A6 and mutagenesis provided evidence of A6 being essential for the transition 
from IV to IVN and MV.  
After mutating clusters of amino acids to Ala near C-terminus of A6, temperature-sensitive 
viruses with no or impaired replication ability at high temperature (40°C) were screened and 
selected. That loss of replication ability was due to the mutation of A6 was confirmed because the 
replication ability was restored by adding wild type A6. At the non-permissive temperature 
(40°C), two viron proteins (4a and 4b) were essentiallly prevented from maturation and remained 
as their precursors. Also, the lesion in A6 caused a block in virus morphogenesis and only 
crescents and a few IVs were observed in comparison to all stages (crescents, IVs, IVNs and 
MVs) were present at the permissive temperature 31°C (Figure 4-3) (Meng, Embry et al. 2007).  
 




Virus containing with IPTG-inducible A6 was studied and A6 appears to be essential not only for 
early virus membrane recruitment, but also membrane protein localization. Transmission electron 
microscopy of cells inffect with recombinant viruses with A6 induced or repressed suggested that 
A6 is required for the membrane formation of virus crescent (Figure 4-4). Also, without A6, 
virion membrane proteins F9 and L1 cannot be detected by antibodies while majority of a virion 
core protein A10 remains as a precursor. A14 glycosylation ratio increases, same as observed 
when membrane biogenesis blocked (Figure 4-5). In absence of A6, results from 
immunofluorescence microscopy show that viron membrane proteins A13, A14, D8 and H3 
change their localization from viron factories to the cytoplasm outside of the factories (Figure 4-
6). Furthermore, viron membrane proteins not only co-localize but also co-sediment with ER 
protein when A6 expression is repressed, suggesting they associate with cell secretion apparatus. 
(Meng, Embry et al. 2012).  
 
Figure 4-4: Absence of A6 block virus membrane formation. A and B are transmission electron 








Figure 4-5: A6 effect the stability and post-translational modification of A14, F9, L1 and A10. 
The cells were infected by virus with (+) or without (-) IPTG. The western blot was performed on 





Figure 4-6: A6 effects the localization of A13, A14, D8 and H3. The cells were infected by virus 
with (+) or without (-) IPTG and then fixed, permiablized and stained with antibodies against 
each protein and DAPI. F stands for viron factories (Meng, Embry et al. 2012).  
Our knowledge of A6 has largely come from morphogenesis observation via cell-biology-based 
microscopy. However, the detailed mechanism of how A6 interact with other virus proteins and 
cell skeleton and organelles remain unknown. Our dedication in solving the crystal structure of 
A6 aims to address the following questions. What proteins or elements in cell does A6 interact 
with? How virus utilize cell membranes and cytoskeleton for its own replication co-ordination? 
In spite of no known A6 homologous structure based on amino acid sequence alignment, once we 
obtain the crystal structure of A6, we will be able to identify some functional domain using 




sequence. Such knowledge will expand our understanding of the role A6 plays during vaccinia 
virus replication. 
B. Results 
1. Cloning and Purification 
A6 and its mutants were cloned into a modified pET28 vector, overexpressed them in E. coli and 
purified them in high quality. 
The wild type A6 construct was obtained from our collaborator Dr Yan Xiang. We cloned wild 
type A6 and its mutants into a modified pET28 vector with an N-terminal His6 tag SUMO (Small 
Ubiquitin-related Modifier) and Ulp1 cleavable site. SUMO fusion can increase the solubility and 
stability of recombinant protein and Ulp1 specifically recognizes SUMO and cleaves right at the 
N terminus of recombinant protein. 
The plasmid was transferred electronically into BL21 DE3 gold strain with high expression 
ability. When cell growth reach OD600 0.8~1.2, 1‰ IPTG was added into cell medium to induce 
protein expression at 18°C for overnight. Cells were harvested the next morning using 
centrifugation at 15,000g. 
The cell pellet was broken using a French press style high pressure homogenizer EmulsiFlex-C5. 
The His6 tag binds to nickel resin though affinity chromatography under low imidazole 
concentration. Then the affinity is competed off by high concentration of imidazole. After that, 
the affinity tagged SUMO is cleaved by 1:50 to 1:100 ratio of Ulp1 and the mixture of tag-
cleaved protein, the tagged SUMO and uncleaved protein is applied to nickel resin again. Only 






Figure 4-7: SDS-PAGE of samples collected along the purification of A6. The lanes from left to 
right are: protein marker, insoluble cell pellet, cell lysate flown through Ni resin, A6 with SUMO 
and His tag eluted from Ni resin, Ulp1 cleaved sample, A6 without His tag flown through Ni 
resin, A6 without His tag washed by 20mM imidazole from Ni resin, uncleaved material and Hig 
tagged SUMO eluted from Ni resin.  Nickel purified A6 is shown in the orange circle. 
2. Protein Characterization  
a. Size Exclusion Chromatography 
After obtaining tag-cleaved and purified A6 protein, we injected it into analytical size-exclusion 
column Superdex 200 (GE Superdex200) operated by GE AKTA purifier to determine its 
polymeric state in solution. Calculated from the retention volume of protein peak, A6 is 





Figure 4-8: The size-exclusion chromatography figure of A6 and the SDS-PAGE of samples 
collected from the fractions around the protein peak. The protein peak is indicated by the arrow 
and from the retention volume. The calculated molecular mass is 52 kDa. Compared to A6’s true 
molecular mass 43 kDa, it is a monomer in solution. 
b. Dynamic Light Scattering  
Dynamic light scattering serves as a powerful tool to determine the molecular weight distribution 
of particles in suspension or solution. After centrifuging 14,000 rpm for 15 minutes to remove 
any precipitant and insoluble particles, aqueous solution containing purified A6 was put in a 
cuvette in Malvern zetasizer. It was then hit by laser and the time scale of movement of scattered 
particles was calculated to reveal the partical size. The result of A6 DLS agreed with that from 







Figure 4-9: The Dynamic Light Scattering report of A6. The estimated molecular mass is 59 kDa, 
and it has monodisperse. Comparing to A6 true molecular mass 43 kDa, it is a monomer in 
solution. 
c. Structure Prediction 
i. Secondary Structure Prediction 
We submitted A6 sequence to softwares DPM (Deleage and Roux 1987), DSC (King and 
Sternberg 1996), GOR4 (Garnier, Gibrat et al. 1996), HNNC (Guermeur, 1997), PHD (Rost, 
Sander et al. 1994), Predator (Fishman, 1997), SIMPA96 (Levin 1997), SOPM (Geourjon and 
Deleage 1994), SOPMA (Geourjon and Deleage 1995)) for secondary structure prediction and the 













Figure 4-10: The consensus result of A6 secondary structure prediction. 
According to the consensus, A6 is a well ordered protein which may contain 57.8% alpha helix, 
7.53% extended strand, 25.27% random coil and 9.41% ambiguous states. 
      ii. Tertiary Structure Prediction 
The A6 sequence was submitted in I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-
TASSER/) for structure prediction (Zhang 2008). Five models were generated with C-score 




while other models have them inside one α-helix. Combining the domain identification result in 








Figure 4-11: The ribbon structure of one I-TASSER predicted A6 model. N-terminal domain is 
colored in yellow and C-terminal is colored in green. Seeing from the top (upper image) and side 
(lower image). With 121st and 122nd amino acids shown in sticks. 
3. Crystallization Screening 
Purified wild type A6 in buffer [20 mM Tris, 0.5 M NaCl, 1 mM DTT, pH 8] was concentrated to 
11.6 mg/ml and used for crystallization screening. Screening plates were set up in sitting drops 
using Art Robins Gryphon robot. 960 conditions were covered including Index, Crystal Screen, 
PEG/ION, SaltRx (from Hampton Research), Wizard 1 2 3 4 (Emerald BioStructures), JCSG I II 
III IV (from Qiagen). But no crystal hits were observed. 




Wild type A6 is recalcitrant to crystallization, so we applied mutagenesis based on surface 
entropy reduction to assist crystallization.  
One limiting step of protein molecules from solution to crystal is the formation of favorable 
crystal lattice contacts. Site specific alanine substitutions targeting patches of amino acids with 
long flexible side chains (usually Glu and Lys) would reduce the surface entropy and could 
overcome the energy barrier for lattice build up. While other conditions remain unchanged, the 
protein engineering by SER approach makes crystal forming thermodynamically favored 
(Cooper, Boczek et al. 2007). 
a. Site Direct Mutation 
Surface Glu and Lys might prevent nonspecific aggregation and precipitation towards 
crystallization, for their long flexible side chains interact with solvent molecules (Derewenda and 
Vekilov 2006). Using program http://services.mbi.ucla.edu/SER/ we predicted several clusters of 
Glu or Lys (shown in Figure 4-11) to be sites of mutation and made several constructs containing 






Figure 4-11: The alignment of sequences of A6 wild type and mutants. The sites of mutation are 
labeled with stars underneath. 
5. Purification and Crystallization of Mutant AC 
Mutant AC (alanine mutations at both A and C sites) was generated by overlapping PCR method 
and cloned in the same way as the wild type A6 as described above. Protein purification and 






Figure 4-12: The chromatograph of A6 mutant AC in GE HiLoad S-200 size exclusion column 
and the SDS-PAGE gel showing the protein samples from the corresponding fractions. 






Figure 4-13: The A6 mutant AC crystals. 
The crystal was harvested and data was collected and processed as described in II.F. Crystal 
diffracted to 4 Å and one unit cell contained more than 20 molecules. The data was 
undecipherable. 
a. Native Gel Analysis 
The large amount of molecules in one unit cell suggested that mutant AC might not be 
homogenous in the crystal. A6 may adopt dynamic conformations in solution. To further 
characterize A6 protein, we carried out native PAGE analysis. Native PAGE gel system is the 
polyacrylamide gel electrophoresis run in non-denaturing conditions so that the protein or protein 
complex analyzed remains its natural state. The speed of protein or protein complex migrating is 
determined not only by its size but also by the charge and shape. 
We used native gel to analyze the homogeneity of AC. Although AC appeared to be homogenous 
monomer in size-exclusion chromatography, on native gel the AC sample was separated into one 
major band and one minor band. It indicated AC may carry different charges or bind some small 




b. Ion Exchange Chromatography of A6 
We further try to separate any possible contaminant using ion exchange chromatography. Ion 
exchange separates polar molecule based on the surface charge. 
 
 
Figure 4-14: The chromatograph of HQ ion exchange analysis of AC. The light blue slash 





Figure 4-15: The native gel analysis of samples collected from HQ ion exchange 
chromatography. 
6. Domain Identification 
During the study of recombinant virus with IPTG inducible A6, a steady C terminal fragment of 
A6 around 25kD was observed (Meng, Embry et al. 2012). It is quite possible that a small portion 
of full length A6 is degraded naturally by protease inside the cell. A6 might contain a stable C-
terminal domain which is more likely to crystalize. 
a. Limited Proteolysis 
We used proteases trypsin and chymotrypsin to cut off the loose and flexible peptide from protein 
and leave rigid region, which might assist crystallization. Trypsin cleaves at the carboxyl side of 
Lys and Arg while chymotrypsin prefers to cut after Tyr, Trp and Phe. 
Various ratio of trypsin or chymotrypsin were applied for various amount of time. It was noticed 





Figure 4-16: SDS-PAGE of A6 digestion by trypsin or chymotrypsin. The length of digestion is 
indicated upon each lane. The circled bands are the stable bands sent for mass fingerprint. 
b. HiLoad Size Exclusion Chromatography 
Then 1:1000 molar ration of trypsin or chymotrypsin was used to digest overnight and loaded the 
sample onto a HiLoad sizing column. From the chromatograph (Figure IV-18) we could tell that 
there were two distinct peaks, each representing a complex of peptides. The two peptides 
complexes can be concentrated to 15mg/ml and 8 mg/ml. I used the material to set up 





Figure 4-17: The chromatograph of HiLoad size-exclusion of trypsin digested A6 and the SDS-
PAGE showing the sample collected from each fraction. 




Chymotrypsin and trypsin digestion both generated steady fragments around 30 kDa. After 
digestion, these two fragments were sent to the core facility for mass fingerprint analysis. When 
selecting peptide threshold to be 80% and peptide count to be 2, Vaccinia Virus A6 was identified 
to be 100% for both peptide. The result is shown in Figure 4-19. The highlighted area are the 80% 
identified peptides. Both fragments appeared to be primarily the C terminal part of A6, with some 





Figure 4-18: The Mass fingerprint result of the band from chymotrypsin digestion (A) and the one 
from trypsin digestion (B). They are both identified as part of A6, primarily C terminus of A6. 
d. Western Blot Confirmation 
Intact A6, trypsin digested A6 and chymotrypsin digested A6 were run in SDS-PAGE and 
transferred to membrane. Then antibodies generated from mice by collaborator targeting C-
terminus or N-terminus of A6 were used as first antibody and anti-mice antibody was used as 








Figure 4-19: The SDS-PAGE gel, the N-terminus antibody as first antibody western blot and the 
C-terminus antibody as first antibody western blot. It shows that the steady bands around 37kD 
are the N-terminal part of A6. 
e.  N-terminal Sequencing 
We sent the steady fragments around 37 kDa generated from limited proteolysis to Iowa State 
University for N-terminal sequencing. The result indicated the starting residue of chymotrypsin 
digested part is 122nd A.A. and that of trypsin digested part is 124th A.A. We made construct of 
this domain. 
7. N Terminal Domain of A6 
Truncated version of wild type A6 and mutants were constructed and purified as described above. 
The truncated mutant C formed cubic crystals under the condition of 0.1 M MES, 2 M 





Figure 4-20: The crystal of truncated mutant C.  
Data collection and processing was carried out as described in II.F. The crystal diffracted to 8Å 
and data was not enough for structure determination. 
a. Lysine methylation 
Reductive alkylation on lysine residues is a chemical modification on molecule surface that 
reduces surface entropy and promotes crystallization. We use formaldehyde as substrate and 
dimethylamine-borane complex as reducing agent following a previous protocol (Rayment 1997). 
The first step of reaction is the free amine of lysine on the protein surface forming a Schiff base 
with formaldehyde and then reduced to a secondary amine. After that, monomethyl lysine reacts 
rapidly with formaldehyde to dimethyl amine.  
We mixed 40 ul freshly made 1 M formaldehyde and 20 ul freshly made dimethylamine-borane 
complex solution with each ml of diluted protein sample (1mg/ml) and gently rock the container 
in 37°C for 2 hours. After that, the same amount of formaldehyde and dimethylamine-borane 
complex was added into the reaction. 2 hours later, a final 10 ul of dimethylamine-borane 




Lysine methylation reduces protein solubility and increases mass, thus lots of precipitation occurs 
after the reaction. After centrifuging, size-exclusion chromatography can be applied to obtain 
homogenous sample. (Walter, Meier et al. 2006) The sample was concentrated and set up for 






Figure 4-21: The HiLoad size exclusion chromatograph of lysine-methylated truncated mutant C 
seleno-methionine protein and the SDS-PAGE gel showing samples collected from corresponding 
fractions. 
8. Antibody Assisted Crystallization 
a. Rationale 
In the past few years, the use of antibodies in co-crystallizing proteins that are otherwise 
recalcitrant to crystallization has witnessed great successes. For example, the determination of G-
protein coupled receptor β(2) adrenoceptor structure greatly benefited from a specific single 
domain antibody (sdAb) (Rasmussen, Choi et al. 2011). The use of antibodies in co-
crystallization has at least two benefits: 1) stabilizing flexible regions of the target protein to 
reduce entropy; 2) creating crystal lattices through antibody-mediated interactions. 3) The 
available structure of antibodies will be useful for structure determination of the complexes by 
using molecular replacement method. 
b. Fragment Antigen-Binding (Fab) Complex Crystallization  
i. Rationale 
When A6 fails to crystallize itself, Fab generated from monoclonal antibody was used to assist 
crystallization. The fragment antigen-binding (Fab fragment) contains one variable region and 
one consistant region of each heavy chain and light chain, thus Fab retains the antigen binding 
ability of antibody while its size is significantly smaller. Fab has become a powerful assistant in 
crystallization. It can form a layer facilitating crystal lattice formation, and if a crystal of protein 
with antibody is obtained, no additional phasing is needed because the structure of antibody is 





Figure 4-22: Fab generation rationale. From Pierce Chemical. 
ii. Fab Generation Procedure 
We provided A6 protein to our collaborator in San Antonio and they used it to generate 
monoclonal antibody against the N-terminal or C-terminal of A6. 
Papain, a nonspecific thiol-endopeptidase derived from papaya, or ficin, that derived from figs 
latex, was used to digest the antibody into (Fab’)2 and Fc fragments or Fc pieces, followed by 
cysteine to mildly separate (Fab’)2 to two Fab fragments. 
Protease (papain or ficin) was first activated in the buffer containing 10 mM Cysteine in 37°C for 
15 minutes. Then cysteine was removed by buffer exchange. This activated protease was added 
into monoclonal antibody around 1:100 molar ratio and digested for 2 hours. Iodoacetamide 
(IAA) was used to stop the digestion and immobilized Protein A was used to capture Fc 





Figure 4-23: The non-reducing (left) and reducing (right) SDS-PAGE gels of test digestion of 
monoclonal antibodies 11C9. The 50 kD band in the left gel and the two 25kD bands in the gel 
highlighted by the red arrows are the non-reduced and reduced sample showing generated Fab. 
After Fab is purified, we can mix it with A6 and run the mixture in size exclusion column and 
obtain the complex. The complex was concentrated and used for crystallization set up. 






Figure 4-24: The size exclusion chromatograph of A6 mutant AC plus 11C9 Fab and the SDS-
PAGE gel showing samples from corresponding fractions. The calculated molecular mass of this 
complex peak is 170 kD, suggesting this complex might be a hetero-tetramer containing two AC 
molecules and two Fab fragments. 
This peak was concentrated and used for crystallization screening, but only Fab crystals were 
obtained. This might be caused by low affinity between AC mutant and the Fab because Fab was 
generated from wild type A6. 






Figure 4-25: The size exclusion chromatograph of truncated A6 mutant C plus 11C9 Fab and the 
SDS-PAGE gel showing samples from corresponding fractions. The calculated molecular mass of 
this complex peak is 81.37 kD, suggesting this complex might be a hetero-dimer containing one 
truncated C molecule and one Fab fragment. 
c. Single Domain Antibody (SdAb) Complex Crystallization 
i. Rationale 
One type of heavy chain antibodies in absence of light chains are found in sera of camelidae 
(Hamers-Casterman, Atarhouch et al. 1993). Single domain antibody (nanobody), the smallest 
segment of immunoglobin retaining antigen binding ability, contains only one variable region 
derived from heavy chain. It is remarkably smaller than traditional antibody, thus more stable, 
while it can be produced faster and more economically (Vincke and Muyldermans 2012). In 
crystallography, SdAb has proven to be a powerful auxiliary tool (Lam, Pardon et al. 2009). It can 
facilitate crystallization while it binds to protein that is recalcitrant to crystallization on its own 
and may provide crystal lattice contact. Once complex crystal formed and X-ray diffraction data 
obtained, SdAb can also provide the phasing information during structure determination because 




antibody or Fab generated from antibody because recombinant SdAb is expressed in E. coli or 
yeast. 
In our case, purified protein (A6) was injected to a llama six times in mixture of other proteins.  
Heavy chain antibody mRNA was extracted from lymphocytes, ligated to pHEN4 phagemid 
vector and subsequently transformed to E. coli TG1 cells (Conrath, Lauwereys et al. 2001). In 
this way, a VHH library was constructed. The phages containing this generated VHH library 
infected E. coli in the presence of M13K07 helper phage and expressed VHHs. A6 protein was 
used to screen its binders through multiple runs of phage display. Enriched colonies were applied 
to a phage ELISA to analyze the binding affinity. 40 to 50 positive individual candidates were 
selected and sent for sequencing to obtain distinct VHHs. After that, all the selected nanobody 





Figure 4-26: Workflow of single domain antibody (SdAb/nanobody) generation (Pardon, 
Laeremans et al. 2014). 
ii. Periplasmic Expression 
The major advantage of periplasmic expression is that only correctly folded protein can be 
secreted to periplasm. Besides, SdAb might be toxic to cell, so periplasmic expression avoid 
cytoplasmic overexpression. The expression protocol starts from strains frozen in -80°C, which 
are grown in Terrific Broth (TB) plus 2% glucose and antibiotic in 25°C or 30°C overnight. Next 




(OD~1.5) and induced with 1‰ IPTG. Protein express is allowed for 4 to 5 hours in 23°C before 
harvest cell. 
iii. Osmotic Shocking Purification 
Correctly folded SdAb is secreted to the periplasm of cell. So instead of breaking cell completely 
like our conventional routine, we use osmotic shocking to avoid the unfolded cytoplasmic 
protein. 
Cells are resuspended in 15 ml hypertonic Tris-sucrose solution (100 mM Tris, 0.75 M sucrose, 
pH 8.0) with gentle pipetting and 2 ml of 3 mg/ml lysozyme is added to digest peptidoglycan. 
The tube is rocked at 4°C for 15 to 20 minutes. 2.8 ml of 10 mM EDTA is then added drop to 
drop into solution while gently shaking the tube to prevent high local concentration and rock for 
30 minutes. This step is to permeablize the outer membrane of E. coli. Then 2 ml of 0.5 M MgCl2 
is added to chelate any extra EDTA. The buffers are mixed well and centrifudged at 10,000 rpm 
for 20 minutes. The supernatant is collected and mixed with Nickel resin. SdAb with permanent 
His tag at C terminal is captured by nickel resin and later eluted with 250 mM imidazole buffer.   
Constructs were expressed and purified as described above (by labmate Lingyi Tang). Then 
purified A6 was mixed with each SdAb and injected into size exclusion column. 
iv. Complex Analysis 
Antibody 458 seems to have low binding affinity to A6 wild type because it caused A6 peak to 




complex binding was not tight enough (Figure 4-27). 
 
 
Figure 4-27: The size exclusion chromatograph of A6 wild type plus SdAb 458 complex on S75 
(GE Health) column and SDS-PAGE showing samples collected before injection and from 
corresponding fractions. 
The binding between antibody 458 and A6 is even weaker when NaCl concentration increases to 






Figure 4-28: The comparison of size exclusion chromatographs of A6 wild type plus SdAb 458 
complex on S75 (GE Health) column in 200 mM NaCl (blue) and 500 mM NaCl (red). The SDS-
PAGE showing samples collected before injection and from corresponding fractions in 500mM 
NaCl. 
Antibody 460 seems to have strong binding affinity to A6 wild type for it caused A6 peak shifted 






Figure 4-29: The size exclusion chromatograph of A6 wild type plus SdAb 460 complex on S75 
(GE Health) column and SDS-PAGE showing samples collected before injection and from 
corresponding fractions. 







Figure 4-30: The size exclusion chromatograph of A6 wild type plus SdAb 461 complex on S75 
(GE Health) column and SDS-PAGE showing samples collected before injection and from 
corresponding fractions. 
Antibody 458 and A6 mutant AC seems to bind according to the SDS-PAGE gel, but the peak 
shift is not obvious on S75 chromatography, probably because Mutant AC itself is a dimer and its 






Figure 4-31: The size exclusion chromatograph of A6 mutant AC plus SdAb 458 complex on S75 
(GE Health) column and SDS-PAGE showing samples collected before injection and from 
corresponding fractions. 
A6 truncated mutant C and SdAb 458 have strong binding due to the complex peak shifts from 
A6 truncated mutant C peak, and the ratio of truncated mutant and 458 in the complex peak was 







Figure 4-32: The size exclusion chromatograph of A6 truncated C plus SdAb 458 complex on 
S75 (GE Health) column and SDS-PAGE showing samples collected before injection and from 
corresponding fractions. 
9. Homologues 
M95 in Myxoma virus (Johnston, Barrett et al. 2005) and Y97 from Yaba monkey tumor virus 
(Brunetti, Amano et al. 2003) are two homologues of A6. M95 has 57% identities in with amino 
acid sequences and Y95 has 56%. We constructed these two proteins in pSUMO vector and 




pCG 66 (SUMO-M95) was purified through two step nickel and then run in SEC. The 
chromatograph showed two distinct peaks with calculated MW of 123 kD and 38.5 kD (Figure 
IV-33). Considering its real MW is 43kD, they might be a tetramer peak and a monomer peak. 
The nonreducing and reducing SDS gel showed that both peaks contained disulfide-bond-linked 
oligomers (Figure 4-34).  
 
Figure 4-33: The analytical SEC of pCG66 chromatograph and the SDS-PAGE showing samples 







Figure 4-34: The nonreduced (left) and reduced (right) samples of pCG66 HiLoad before 
injection and two peaks.  
Protein from the nickel purification was then supplied with 1 mM DTT before injected to HiLoad 
SEC. The chromatogram showed a single peak with calculated MW of 49 kD. Purified protein 






Figure 4-35: The HiLoad chromatograph of pCG66 containing DTT. 
pCG 67 (SUMO-Y97) was purified through two step nickel and then run in SEC. The 
chromatograph showed multiple peaks with calculated MW of 271.8 kD, 135.5 kD and 40.7 kD. 
The nonreducing and reducing SDS gel showed that all peaks contained disulfide-bond-linked 






Figure 4-36: The analytical SEC of pCG67 chromatograph and the SDS-PAGE showing samples 
collected along purification. 
DTT didn’t improve the homogeneity of protein, for the 5 mM DTT containing sample presented 
the similar chromatograph on SEC (Figure 4-37). 
 
Figure 4-37: The HiLoad SEC of pCG67 chromatograph. 
 
C.  Discussion 
1. Possible Reasons for Not Obtaining A6 Structure 
The reason why A6 never formed nice diffracting crystals may not be known until its structure is 




overcome large surface entropy to crystalize. Our surface entropy reduction based protein 
engineering did promote crystallization, but the crystal packing was not ideal due to 
heterogeneity. Ion exchange chromatography, detergent washing and high salt washing were 
applied but none was able to improve the protein quality. 
2. Possible Function Prediction 
We identified two domains, N-terminal and C-terminal. Our collaborator found out both domains 
are essential for deletion of either disabled A6 function (unpublished data). 
A11 is another protein required for poxvirus primary membrane forming. It associates with 
membrane and colocalizes with membrane proteins during virus replication. Its binding to A6 
was proved by immunoprecipitation and its localization in cell alters in the presence or absence of 
A6. Moreover, without A6, A11 does not associate with membrane or colocalize with membrane 
proteins (Wu, Meng et al. 2012). 
H7 is a protein critical for forming crescents and immature virions. It is expressed in cytoplasm 
but not packed into mature viruses (Satheshkumar, Weisberg et al. 2009). From collaborator’s 
immunoprecipitation data (unpublished), A6 binds to H7. 
A6 might bind to A11 and H7 directly, and together they assemble a protein complex responsible 





Figure 4-38: The depiction of viron membrane assembly model. Adopted from (Maruri-Avidal, 
Weisberg et al. 2013). 
Under fluorescence microscope, our collaborator observed A6 travels in cell along microtubules 
into viron factories. It is reasonable to surmise that A6 binds to one of the microtubule motors 
such as kinesin or dynein. 
3. Alternative Approach and Future Direction 
The first choice is to exhaust all SdAb and A6 constructs combinations. SdAbs with strong 
binding affinity as well as weak binding affinity may assist A6 crystallization. 




Maltose binding protein (MBP) infusion is another entropy reduction method. It can increases A6 
expression level and solubility, as well as can encourage the crystal lattice formation when it is 
readily crystallizable itself. Moreover, once the crystal formed and data collected, MBP can 
provide the phase information since its structure is already known. Thus, we can solve the A6 
structure by molecular replacement (Moon, Mueller et al. 2010). 
We constructed MBP linked A6 or its mutants with a AAA linker in between. Nickel purification 
and size exclusion chromatography steps are the same as described above, except for the 40 mM 
maltose in the sizing column running buffer to prevent the nonspecific binding between MBP and 
column beads.  Five mM maltose was kept in the final buffer to stabilize MBP (carried out by 
postdoctoral researcher Dr Bing Zhang in our lab). The protein was unable to express, possibly 
because the linker wasn’t optimal.  
The N-terminal domain of A6 is also worth looking into. Our postdoctoral researcher Bing Zhang 
recently crystalized it and now he is getting ready to collect data on it. 
Once the A6 structure is determined, screening for function of the domains can be carried out as 
described in III.1. A6 binding positions also can be mapped to find out other virion protein 
binding sites. 
Although Roc and A6 projects remain unclosed, I decided to move on to a new chapter of my life. 













Book Part         Abbreviation 
 
   Clorobium tepidu. .......................................................................................... C. tepidu 
   Escherichia coli. ................................................................................................. E. coli 
   Escherichia coli. ................................................................................................. E. coli 
   Size Exclusion Chromatagraphy ........................................................................... SEC 
   Melting temperature. ................................................................................................ Tm 
   Surface Entropy Reduction. .................................................................................. SER 
   Fragment antigen-binding. ......................................................................................Fab 
   Single domain antibody. ..................................................................................... SdAb 
   Wild type. ............................................................................................................... WT 
   Leucine-rich repeat kinase 2. ........................................................................... LRRK2 
   Guanine diphosphate. ............................................................................................GDP 
   Guanine triphosphate. ........................................................................................... GTP 
   Molecular replacement........................................................................................... MR 
   Millimole................................................................................................................ mM 
   Micromole. .............................................................................................................. μM 
   Multiple Anomalous Scattering. ......................................................................... MAD 
   Single Anomalous Scattering. ...............................................................................SAD 
   Multiple isomorphous replacement....................................................................... MIR 
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